Heron Therapeutics Inc. hit a home run in dual phase III trials examining its non-opioid candidate, HTX-011, to control postoperative pain in patients following bunionectomy and hernia repair. Top-line data showed that HTX-011 achieved its primary and key secondary endpoints, producing statistically significant reductions in both pain intensity and need for opioids through 72 hours post-surgery compared both to placebo and to bupivacaine solution, the current standard of care. Importantly, fewer patients who received HTX-011 reported severe pain at any post-op time point, and more who received HTX-011 were opioid-free through 72 hours past surgery.